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From the histological features of osteitis fibrosa, the decades. For instance, the identification of secondary conclusion that bone remodelling is increased in this hyperparathyroidism and 1, 25a-dihydroxycholecalciform of renal osteodystrophy is straightforward. Bone ferol (calcitriol ) deficiency as major contributors to remodelling consists of the selection of site for remodelrenal osteodystrophy has led to the development of ling activity followed by the activation of the process. treatment regimens which maintain normal serum calRemodelling activation consists of a complex stimulacium and phosphate concentrations, reduced paration of two differentiation programmes, one of the thyroid hormone secretion, and correct low calcitriol osteoblast differentiation programme and one of the levels. These improvements in the treatment of renal osteoclast differentiation programme ( Figure 1 ). osteodystrophy have resulted in a decrease in the Osteoclastic differentiation proceeds and concludes frequency and severity of osteitis fibrosa, the most more rapidly resulting in the stimulation of bone common and important type of renal osteodystrophy.
resorption. Parathyroid hormone and locally produced The removal of aluminium from both water used for or systemic activating factors including interleukin-1 dialysis and aluminium phosphate binders has treand tumour necrosis factor a stimulate release of mendously diminished the incidence of osteomalacia soluble factors from stromal cells and the haematopoiand aluminium intoxication as a cause of the adynamic etic tissue which induce the proliferation and differenbone disorder. The frequency of aluminium-related tiation of osteoclast precursors. As a result, there is an bone disease has waned only to be replaced by increasactivation of osteoclastic bone resorption by an eleving prevalence of the adynamic bone disorder. As a ated number of multinucleated highly polarized osteoresult of these developments new hypotheses related to clasts. The soluble factors involved in the development the pathogenesis of renal osteodystrophy have been generated and tested, at least on a preliminary basis. of osteoclasts are many, including macrophage colonyThis review will discuss these new hypotheses and stimulating factor (m-CSF ), granulocyte-macrophage suggest future directions for study and treatment.
colony-stimulating factor (gm-CSF ) interleukin-6, interleukin-11, leukaemia induction factor (LIF ) and others. Parathyroid hormone, tumour necrosis factor
Pathogenesis of osteitis fibrosa
a, and interleukin-1 stimulate production of osteoclasts at different stages of cell differentiation, leading to synergism when the concentrations of cytokines and The histological features of osteitis fibrosa cystica parathyroid hormone are both elevated, as in chronic include a proliferation of osteoblasts leading to an increase in bone surfaces covered by osteoblast and an renal failure [1] . The actions of parathyroid hormone, increase in osteoblastic cells with a cuboidal type of and calcitriol on osteoclast differention occur late in cellular morphology. There is an increase in osteoclast the programme. Recent studies suggest the calcitriol may be a factor regulating substances that function at Correspondence and offprint requests to: Keith Hruska MD, Renal the multinucleation stage. In addition, new information Division, Barnes-Jewish Hospital North, Washington University demonstrates that a soluble circulating molecule of the the late stages of osteoclast development [2] . Since this anabolism by substances that regulate activation of the remodelling cycle. For instance, parathyroid horsubstance is made in the kidney besides the lung and heart, its deficiency in chronic renal disease would mone, tumour necrosis factor a, and interleukin-1 stimulate the production of an osteoblastic phenotype promote osteoclastogenesis independent of PTH or calcitriol.
consistent with the resorptive process. That is, parathyroid hormone stimulates osteoblastic cells to secrete Following remodelling activation, bone is resorbed by multinucleated osteoclasts. When a quantity of collagenase [6 ], tissue plasminogen activator [7] and inhibits the synthesis of collagen [8] and inhibits probone has been resorbed, increased local concentrations of calcium [3] or activation of latent factors in the gression of the osteoblastic cell cycle [9,10]. One question that becomes immediately apparent then is how bone matrix (e.g., transforming growth factor b) leads to diminished osteoclast activity, separation of osteo-parathyroid hormone induces its anabolic actions. The current theory is that parathyroid hormone is not a clasts from the bone surfaces, and apoptosis. Some of the same signals that decrease resorptive activity, mitogenic factor. We and others have provided evidence clearly supporting this concept of parathyroid (transforming growth factor b, heparin bound growth factors-i.e. fibroblast growth factors and bone mor-hormone action on cells in the osteoblast differentiation programme [9,11-13]. In addition, Dobnick and phogenetic proteins) bring osteoprogenitors or osteoblasts into the resorption lacunae and activate them Turner [14] have demonstrated that parathyroid hormone may increase osteoblast number by causing [4, 5] ( Figure 2 ). This process initiates bone formation from osteoblasts and osteoblast precursors which have dedifferentiation of the lining cells to assume an osteoblast phenotype. This has become the current concept differentiated from the activation of the osteoblast differentiation programme at the onset of remodelling of how parathyroid hormone induces an increase in osteoblast number during bone remodelling. However, activation ( Figure 1 ). Bone formation includes the proliferation and differentiation of osteoblast pre-it ignores the accumulation of peritrabecular fibroblastic-like cells in osteitis fibrosa cystica. We have shown cursors, matrix (osteoid) synthesis, mineralization, resorption of woven bone and its replacement with that parathyroid hormone is indeed mitogenic for cells very early in the osteoblast differentiation programme lamellar nutrient shaped supplied bone. At the end of the remodelling cycle in chronic renal diseases, the [15, 16 ] . We have recently demonstrated that parathyroid hormone is mitogenic for a stromal cell isolated amount of bone formed is smaller than that which was resorbed. This difference increases with age, so that from human bone marrow which we have characterized as a non-committed osteoprogenitor [15] (and Onishi older patients with end-stage renal disease may have osteopenia in addition to renal osteodystrophy.
et al., unpublished). (Figure 3 ). As a result of this data we have postulated that parathyroid hormone One of the major difficulties in our current understanding of bone formation is stimulation of bone stimulates proliferation of an osteoprogenitor leading Fig. 2 . Activation of bone resorption in ROD. Following remodelling activation and osteoclast differentiation, bone is resorbed by highly polarized multinucleated osteoclasts ( left). Osteoclasts form a tight seal with the bone matrix in a process involving adhesion through the a v b 3 integrin in the osteoclast clear zone. The seal is sufficient to allow acidification of the resorption space by secretion of H+ through the activity of a vacuolar H-ATPase inserted into the ruffled border. Acidification dissolves bone mineral and the matrix is degraded by a cathepsin active at acid pH. As resorption proceeds (right), release of the products of resorption into the resorption bay, including Ca, decrease osteoclast adherence leading to apotosis. Other products of resorption including heparin-bound growth factors ( TGFb and BMPs) stimulate preosteoblasts and osteoblasts to move into the resorption bay and begin bone formation. Fig. 3 . Effects of CRD on the osteoblast differentiation programme. New preliminary data indicate that PTH, elevated by secondary hyperparathyroidism, stimulates proliferation of uncommitted osteoprogenitors. However, these accumulate because of failure to move along the differentiation programme. Factors contributing to deficiency in osteoblast differentiation in CRD include low calcitriol levels, hypogonadism (possibly leading to reduced BMP-6) and others such as BMP-7. In addition there is a mineralization defect in CRD leading to increased unmineralized matrix (osteoid) and formation of woven bone.
to accumulation of fibroblastic cells producing marrow Pathophysiology of adynamic bone disorder fibrosis in the osteitis fibrosa osteodystrophy. These observations raise the question of why these cells do The pathogenesis of adynamic bone disorder is poorly not move further along the osteoblast differentiation understood. The disorder is most common in patients programme. We have begun to address this question with end-stage renal disease who do not have secondary as discussed below in our considerations of the adyn-hyperparathyroidism (e.g. after parathyroidectomy), or following treatment with calcium and calcitriol. In amic bone disorder.
of cell proliferation and expression of the markers been associated with adynamic bone disorder. This may be due to greater transfer of calcium from the of the osteoblast phenotype including osteocalcin, osteonectin, bone sialoprotein, and matrix mineralizdialysate, and suppression of parathyroid hormone secretion with this form of dialysis as compared to ation. The mechanisms by which calcitriol regulates matrix mineralization are unknown. However, it may haemodialysis [17] . From these data, one may consider that hypersecretion of parathyroid hormone is required affect osteoblastic calcium and phosphate transport or regulate the phosphorylation of matrix proteins which to maintain normal rates of bone formation in patients with end-stage renal disease [18] [19] [20] . This would sug-could serve as nidii for formation of calcium phosphate crystals leading to the growth of apatite. gest that the need to maintain bone remodelling at a normal level may be an inherent stimulus for hyperparathyroidism in chronic renal diseases. Recent clinical studies support this conclusion [18, 21] . The Diagnosis presence of adynamic bone disorder in patients with end-stage renal disease who have normal parathyroid function suggest that the production of one or more The recognition that renal osteodystrophy encompasses a spectrum of disorders leads to a current suppressors of bone formation is increased or that other promoters of bone formation (growth differenti-controversy in the practice of nephrology. The question is how to make the diagnosis of renal osteodystrophy ation factors) are not produced ( Figure 3) . Either mechanism could contribute to the need for increased in the absence of bone biopsy. Standard clinical practice in treating patients with end-stage renal disease parathyroid hormone secretion. Recent reports that therapy for end-stage renal disease activates the and renal osteodystrophy has evolved away from the performance of diagnostic bone biopsies before the immune system suggest that there are numerous candidates for suppression factors including interleukin-initiation of therapy. Thus, characterization of patient profiles have been assigned to certain forms of renal 11 which may inhibit osteoblastic bone formation [22] and interleukin-4 [23] . Deficiency of a factor involved osteodystrophy. Osteitis fibrosa will be associated with high levels of parathyroid hormone, alkaline phosphatin bone formation or growth may contribute to adynamic bone disorder. Osteogenic protein-1 (also called ase, and other evidences of increased bone resorption.
On the other hand, patients with adynamic bone bone morphogenetic protein-7), a potent activator of the osteoblast differentiation programme, is produced disorder tend to have normal or reduced bone density, only slightly elevated serum alkaline phosphatase conby normal renal tubular cells [24, 25] . In the adult there is some evidence to suggest that OP-1 is a systemic centrations, relatively normal serum parathyroid hormone concentrations, and absence of aluminium, and factor that derives from renal tubular cells. Thus, one possibility regarding the inability of cells proliferating an increased frequency of hypercalcaemia. In population studies, parathyroid hormone measurements have in response to PTH to transit through the osteoblast differentiation programme is that its capacity is been used to differentiate osteitis fibrosa from adynamic bone disorder, but are not sufficient to establish decreased in chronic renal disease.
Another important factor contributing to osteopenia the type of osteodystrophy in an individual patient [21, [29] [30] [31] . This is especially the case if calcitriol has in patients with end-stage renal disease is hypogonadism [26 ] . In both women and men with end-stage renal been administered [21] . Current recommendations for the maintenance of parathyroid hormone levels take disease, serum concentrations of gonadal steroids tend to be low as a result of a complex set of endocrine into consideration the necessity of sufficient parathyroid hormone to maintain bone remodelling and and non-endocrine factors. As a result, anovulation, amenorrhoea or oligomenorrhoea, infertility, impot-prevent the development of the adynamic bone disorder. This has been difficult to attain at set levels of ence, loss of libido, oligospermia, are common in chronic renal disease. Recent studies in animals [27] , parathyroid hormone. Current recommendations suggest that maintenance of parathyroid hormone levels demonstrate that oestrogen deficiency produces a decrease in bone morphogenetic protein-6. Thus hypo-two to three times the normal range may be sufficient for maintaining bone remodelling in patients with endgonadism may contribute further to the pathogenesis of adynamic bone disorder in the absence of para-stage renal disease. However, there are numerous exceptions to this [21] . thyroid hormone.
Although initial reports suggested that adynamic bone disease does not cause symptoms [18, 28] subsequent follow up has not resolved the issue. The
Current management recommendations
importance of adynamic bone disorder may be the long-term risks of osteopenia and its provision of new insights into the pathogenesis of renal osteodystrophy. The current management of renal osteodystrophy is the control of serum phosphate and calcium along Another factor, calcitriol, used in the treatment of secondary hyperparathyroidism may also be important with the use of Vitamin D analogues.
Phosphate Conclusions
The recognition that there are new concepts regarding A low-phosphate diet is integral to the management of end-stage renal disease. It is necessary to prevent the development of renal osteodystrophy comes at a time when new opportunities for its treatment are on secondary hyperparathyroidism and can be produced by dietary phosphate restriction and the use of phos-the horizon. The possible discovery of additional substances with important pathophysiological roles in phate binders. Phosphate binders are either calcium carbonate, calcium acetate, and new compounds in osteitis fibrosa and adynamic bone disease may lead to improved approaches to the prevention and treatclinical trial [32] [33] [34] . ment of renal osteodystrophy.
Control of serum calcium
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